Prexigebersen

Drug Profile

Prexigebersen

Alternative Names: BP 100-1-01; BP-100-1.01; BP-1001; L-Grb-2; L-Grb-2 antisense; Liposomal Grb-2 antisense; Liposomal Grb2 antisense oligonucleotide

Latest Information Update: 27 Jan 2017

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings
  • Class Antineoplastics; Antisense oligonucleotides; Nucleotides
  • Mechanism of Action Extracellular signal-regulated MAP kinase inhibitors; GRB2 adaptor protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia
  • Phase I Acute lymphoblastic leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Preclinical Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Solid tumours; Thyroid cancer

Most Recent Events

  • 03 Dec 2016 Pharmacodynamics data from a phase I trial in Chronic myeloid leukemia presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-Hem-2016)
  • 03 Nov 2016 BP 100-1-01 receives Orphan Drug status for Acute myeloid leukaemia in European Union
  • 03 Oct 2016 Bio-Path Holdings plans a phase Ib/IIa trial for Chronic myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT02923986)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top